文
论文分享
演练场
杂货铺
论文推荐
字
编辑器下载
登录
注册
Tadeusz J. Robak
发表
A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
M. Dimopoulos, J. Cavenagh, H. van de Velde, 2015, American journal of hematology.